Xbrane Biopharma

Xbrane Biopharma Xbrane Biopharma AB is a leading science based biosimilar developer of cost effective medicines with high unmet medical need.

Xbrane base its development on a patented high yield production platform and world-leading expertise. Xbrane has a portfolio targeting originator products with combined annual sales of €11billion. The leading product, Xlucane (ranibizumab biosimilar), is currently in Phase III with target to launch 2022. Xbrane’s headquarter is located in Solna, just outside of Stockholm. Xbrane is listed on Nasdaq Stockholm with the ticker XBRANE.

We, at Xbrane Biopharma AB, believe that if a treatment exists on the market today, it should be available to everyone, ...
08/10/2019

We, at Xbrane Biopharma AB, believe that if a treatment exists on the market today, it should be available to everyone, not just those who can afford it. This goal is the driving force behind Xbrane’s strategy: to develop and manufacture high quality and cost-effective biosimilars based on our patented technology platform and leading expertise.

Xbrane strives to be a part of the driving force for change within the healthcare system and make these treatments accessible for everybody. And in the coming months, we would like to introduce you to the people at Xbrane that will help make it happen. Next up, meet Maria Edebrink ...

October 8, 2019: Xbrane Biopharma AB posted on LinkedIn

"This was a very special day for us. We are excited to be listed on the main market on Nasdaq Stockholm in order to find...
30/09/2019

"This was a very special day for us. We are excited to be listed on the main market on Nasdaq Stockholm in order to find the resources needed to develop more cost effective drugs and deliver them to those in need." - Xbrane Biopharma AB's CEO, Martin Åmark

September 30, 2019: Xbrane Biopharma AB posted a video on LinkedIn

Nasdaq Stockholm welcomes Xbrane Biopharma AB to the main market!
23/09/2019

Nasdaq Stockholm welcomes Xbrane Biopharma AB to the main market!

September 23, 2019: Xbrane Biopharma AB posted images on LinkedIn

We, at Xbrane Biopharma AB, believe that if a treatment exists on the market today, it should be available to everyone, ...
19/09/2019

We, at Xbrane Biopharma AB, believe that if a treatment exists on the market today, it should be available to everyone, not just those who can afford it. This goal is the driving force behind Xbrane’s strategy: to develop and manufacture high quality and cost-effective biosimilars based on our patented technology platform and leading expertise.

Xbrane strives to be a part of the driving force for change within the healthcare system and make these treatments accessible for everybody. And in the coming months, we would like to introduce you to the people at Xbrane that will help make it happen. First off, meet Anders Wallström ...

September 19, 2019: Xbrane Biopharma AB posted on LinkedIn

Glädjande kan vi nu offentliggöra att Xbrane har ingått ett samarbetsavtal med tyska läkemedelsbolaget STADA för vår bio...
12/07/2018

Glädjande kan vi nu offentliggöra att Xbrane har ingått ett samarbetsavtal med tyska läkemedelsbolaget STADA för vår biosimilar Xlucane. Detta är en betydelsefull milstolpe för Xbrane och avtalet är ett stort erkännande för både för Xbrane som biosimilarutvecklare och våra produkter. http://inpublic.globenewswire.com/releaseDetails.faces?rId=2204810

12/07/2018
02/10/2017

Xbrane Biopharma AB bjuder in till bolagspresentation 12 oktober i Stockholm:

21/12/2016

Xbrane signs agreement with BioAvenir for sales and marketing of Spherotide in Israel.

Xbrane's engagement continues year round. We bring affordable prostate cancer medicine to the market.
05/12/2016

Xbrane's engagement continues year round. We bring affordable prostate cancer medicine to the market.

28/11/2016

Live from investor conference Company presentation by Xbrane CEO Martin Åmark. Click on link to watch.

Video från Aktiespararna WebbTV

Listen to Xbrane CEO Martin Åmark and Chairman Saeid Esmaeilzadeh in the latest podcast episode from Vator Securities (i...
02/11/2016

Listen to Xbrane CEO Martin Åmark and Chairman Saeid Esmaeilzadeh in the latest podcast episode from Vator Securities (in Swedish)

Vator Securities är en fee only-rådgivare med fokus på förmögenhetsrådgivning och corporate finance-tjänster för snabbväxande bolag.

Adress

Banvaktsvägen 22
Stockholm
17148

Webbplats

Aviseringar

Var den första att veta och låt oss skicka ett mail när Xbrane Biopharma postar nyheter och kampanjer. Din e-postadress kommer inte att användas för något annat ändamål, och du kan när som helst avbryta prenumerationen.

Kontakta Affären

Skicka ett meddelande till Xbrane Biopharma:

Genvägar

Dela

Typ

Our Story

Xbrane Biopharma AB is a leading science based biosimilar developer of cost effective medicines with high unmet medical need. Xbrane base its development on a patented high yield production platform and world-leading expertise. Xbrane has a portfolio targeting originator products with combined annual sales of €11billion. The leading product, Xlucane (ranibizumab biosimilar), is currently in Phase III with target to launch 2022. Xbrane’s headquarter is located in Solna, just outside of Stockholm. Xbrane is listed on Nasdaq Stockholm with the ticker XBRANE